We permit the publication of our auditors’ report, provided the report is published in full only and is accompanied by the full financial statements to which our auditors’ report relates, and is only published on an access-controlled page on your website https://www.hermes-investment.com, to enable users to verify that an auditors’ report by independent accountants has been commissioned by the directors and issued. Such permission to publish is given by us without accepting or assuming any responsibility or liability to any third party users save where we have agreed terms with them in writing.

Our consent is given on condition that before any third party accesses our auditors’ report via the webpage they first document their agreement to the following terms of access to our report via a click-through webpage with an 'I accept' button. The terms to be included on your website are as follows:

I accept and agree for and on behalf of myself and the Trust I represent (each a "recipient") that:

PricewaterhouseCoopers LLP (“PwC”) accepts no liability (including liability for negligence) to each recipient in relation to PwC’s report. The report is provided to each recipient for information purposes only. If a recipient relies on PwC’s report, it does so entirely at its own risk;

No recipient will bring a claim against PwC which relates to the access to the report by a recipient;

Neither PwC’s report, nor information obtained from it, may be made available to anyone else without PwC’s prior written consent, except where required by law or regulation; and

PwC’s report was prepared with Hermes Property Unit Trust's interests in mind. It was not prepared with any recipient's interests in mind or for its use. PwC’s report is not a substitute for any enquiries that a recipient should make. The financial statements are as at 25 March 2016, and thus PwC’s auditors’ report is based on historical information. Any projection of such information or PwC’s opinion thereon to future periods is subject to the risk that changes may occur after the reports are issued and the description of controls may no longer accurately portray the system of internal control. For these reasons, such projection of information to future periods would be inappropriate.

3. Accept our terms and conditions

The Hermes Investment Management website uses cookies to remember your preferences and
help us improve the site.
By proceeding, you agree to cookies being placed on your computer.
Read our privacy and cookie
policy.

Five defensive stocks to thrive amid ongoing volatility

Hermes Global Equity

Following the S&P 500’s worst five-day start to a new year on record, investors are braced for further volatility in 2016. As a confluence of headwinds weighs on markets, including an oil price slump and China’s slow-down, Lewis Grant, Senior Portfolio Manager of the Hermes Global Equity Fund, identifies defensive stocks that he believes can thrive amid continuing market volatility.

Defensives can provide a haven of resilience in particularly choppy markets. Within traditionally defensive pockets of the market we are focusing on companies that can deliver through the cycle, with the potential to achieve strong relative performance in a downturn but who still offer enough upside to form long-term core holdings if this slump proves short-lived.

Oil slump offers effective tax break to US consumersWith potentially underwhelming US growth, a protracted China slump predicted in 2016, and oversupply issues, oil may sink towards 20 dollars a barrel. While bad news for certain energy companies, this is serving as an effective tax break for the US consumer and a major boost to low-income earners. Hence, we believe lower-end consumer outlets such as Dollar Tree and Dollar General can perform strongly in this environment.

Following the acquisition of Family Dollar, Dollar Tree has overtaken Dollar General as the number one mass-market retailer by number of locations, with almost 14,000 stores across the US and Canada. While in the short-term we expected these companies to benefit from the increased disposable income amongst cost-sensitive clientele, there remains the potential for significant expansion - Dollar Tree, for example, has a long term target of 20,000 stores.

Sentiment weighing on healthcareHealthcare stocks tend to come to the fore when the market retreats. And while the pharmaceutical industry faces stiff headwinds, we believe fears are overblown when you consider the balance sheets and long-term prospects of a number of pharmaceutical and biotech firms.

A confluence of factors has weighed on sentiment towards the sector, including high drug prices and slow drug development cycles. However, there are some major positives such the 21st Century Cures Act which is moving rapidly through the US legislative process and will seek to promote medical innovation and accelerate drug approval process.

In the sector we like Amgen and Roche, companies straddling the pharma/biotech divide. The size of these companies, their diversified product offerings and relatively cheap valuations make them two of the most attractive Healthcare names as the market slows down. Roche in particular is interesting, being priced like a traditional pharmaceutical company but with a large and increasing biotech exposure which could command a significantly higher valuation.

Utilities offer resilienceUtilities, like pharmaceuticals and consumer staples, offer products and services that will continue to be used no matter how gloomy the economic backdrop. Unlike say the purchase of new car or appliance, utilities are essential and cannot be put off. American Water Works, the largest publicly traded water utility in the US, illustrates this idea perfectly, providing regulated water services to 20 states. The company has delivered consistent growth in recent years and has the potential to continue this through increased investment in infrastructure as well as via acquisitions. We view this company as a fantastic long-term opportunity with limited exposure to a market slow-down.

This information does not constitute a solicitation or offer to any person to buy or sell any related securities or financial instruments.